A61P3/02

COMPOSITIONS FOR THE TREATMENT OF COPPER DEFICIENCY AND METHODS OF USE

In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

COMPOSITIONS FOR THE TREATMENT OF COPPER DEFICIENCY AND METHODS OF USE

In an embodiment, the present disclosure relates to a method of restoring cytochrome c oxidase (CcO) activity in a subject in need thereof. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog thereof and rescuing defects of cells in the subject with deficiencies or mutations in at least one of SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTRL ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, and CLCN7. In a further embodiment, the present disclosure relates to a method of treating disorders of copper metabolism. In some embodiments, the method includes administering a therapeutically effective amount of elesclomol or analog to a subject, where the disorder is caused by a deficiency or mutation to a gene including, without limitation, SOD1, AT-1, API SI, COA6, SC02, COX6B1, CTR1, ATOX1, CCS, GSX1, ATP7A, ATP7B, CLCN5, CLCN7, or combinations thereof.

A NOVEL AQUEOUS COMPOSITION WITH WATER INSOLUBLE VITAMINS

Nanogel and nanoparticles comprising vitamin D encapsulated in agar-agar and a polymer selected from poly(acrylamidoglycolic acid) and pectin are provided. Also provided is aqueous nanogel compositions which can be used for prevention or treatment of vitamin D deficiency and methods for encapsulating vitamin D in nanogels and nanoparticles. The nanogel and nanoparticles and compositions thereof are cost-effective, have a considerable shelf life, a faster rate of absorption in the body leading to faster bioavailability. Further, the nanogels and nanoparticles are made with vegetarian sources and causes no changes in the organoleptic properties. The Vitamin D nanogels and nanoparticles developed can be used for fortification of any food, aqueous medium or beverage, including bottled drinking water.

A NOVEL AQUEOUS COMPOSITION WITH WATER INSOLUBLE VITAMINS

Nanogel and nanoparticles comprising vitamin D encapsulated in agar-agar and a polymer selected from poly(acrylamidoglycolic acid) and pectin are provided. Also provided is aqueous nanogel compositions which can be used for prevention or treatment of vitamin D deficiency and methods for encapsulating vitamin D in nanogels and nanoparticles. The nanogel and nanoparticles and compositions thereof are cost-effective, have a considerable shelf life, a faster rate of absorption in the body leading to faster bioavailability. Further, the nanogels and nanoparticles are made with vegetarian sources and causes no changes in the organoleptic properties. The Vitamin D nanogels and nanoparticles developed can be used for fortification of any food, aqueous medium or beverage, including bottled drinking water.

TREATING VITAMIN D INSUFFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
20210236517 · 2021-08-05 ·

Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D.sub.2, 25-hydroxyvitamin D.sub.3, or a combination of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D.sub.2, 25-hydroxyvitamin D.sub.3, or a combination of 25-hydroxyvitamin D.sub.2 and 25-hydroxyvitamin D.sub.3.

Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates
20210252002 · 2021-08-19 ·

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

Mixture of non-digestible oligosaccharides for stimulating the immune system

Nutritional compositions with fucosyllactose and betagalactooligosaccharides for use in stimulation of the immune system. The composition is suitable for infants.

CATH2 DERIVATIVES

The present invention provides new derivatives of CATH2 or CMAP27, one of the cathelicidins. These derivatives comprise N-terminally truncated peptides, cyclic peptides, D-amino acid variants of CATH2 and its truncated derivatives, inverso and retroinverso CATH2 derivatives. These derivatives are useful as anti-infectives, in vaccines, and especially for in ovo applications. Further, for the above derivatives and also for the already known C-terminally truncated derivatives new immunoactivating functions have been described that are particularly advantageous for prophylactic treatments.

Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment
20210209516 · 2021-07-08 ·

The present invention relates to methods of protecting patients and sensitizing cancer cells in combination with chemotherapy and/or radiation therapy. More specifically, the invention provides nutritional methods and formulations that are capable of reducing cancer growth without causing chronic weight loss in patients, protecting normal cells, tissues and organs from chemotherapy and/radiation therapy, and sensitizing cancer cells against low, normal and high-dose chemotherapy. Some of the methods also impede cancer growth even without chemotherapy.

METHODS OF CANCER IMMUNOTHERAPY
20210254015 · 2021-08-19 ·

Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.